2012 Press Releases

Scroll down to see the following press releases:

December 31 2012 New Pelvic Pain Diary by KevMed Will Help Chronic Pelvic Pain, IC, and IBS Patients Take Charge of Their Condition

October 24 2012: New Device Dramatically Reduces Pain in Chronic Pelvic Pain and Interstitial Cystitis Patients, Finds Clinical Study Presented to the International Pelvic Pain Society

October 16 2012: KevMed Prepares to Introduce Novel Device for Pelvic Pain and Interstitial Cystitis as US Distributor of PainShield

October 16 2012: NanoVibronix Appoints KevMed, LLC to Distribute its PainShield™ Product in the US Market

October 10 2012: Chronic Pelvic Pain and Interstitial Cystitis Patients Soon to Have New Treatment Options with Formation of KevMed, LLC

_____________

New Pelvic Pain Diary by KevMed Will Help Chronic Pelvic Pain, IC, and IBS Patients Take Charge of Their Condition

A complimentary, downloadable, comprehensive pain diary, designed for patients suffering from chronic pelvic pain, Interstitial Cystitis (IC), Endometriosis and Irritable Bowel Syndrome (IBS) has been released by KevMed, a company dedicated to the relief of these conditions. The KevMed Pelvic Pain Diary represents an important advance in empowering patients by allowing them to monitor and take charge of their condition, and helping them to communicate efficiently, effectively and knowledgeably with medical providers; the diary will help to save time in the doctor’s office by presenting a clear picture of the patients’ progress, leaving more time for the doctor and patient to plan future treatment.

Dallas, TX (PRWEB) December 31, 2012

A new, comprehensive, downloadable and free pelvic pain diary has recently been developed and released by KevMed™, a company dedicated to the relief of chronic pelvic pain and related conditions. The 5-page diary is available as a downloadable tool free of charge.

 

Unlike other pain inventories, this new diary has been designed specifically for the 15 million patients suffering from a number of overlapping disorders which also includes abdominal pain, Adhesion Related Disorder (ARD), CAPPS, endometriosis, vulvodynia, dyspareunia, dyschezia, sacroiliac joint pain, pudendal neuralgia and pelvic floor dysfunction. Many of these disorders are common in patients who have undergone hysterectomy. Rather than taking a single snap-shot of the pain, this new tool will help patients track their progress over time, especially as it relates to the effectiveness of pain therapies and devices, such as PainShield® MD, a wearable therapeutic ultrasound device marketed by KevMed as a non-invasive, low-risk treatment modality for chronic pelvic pain and pain associated with related conditions.

The KevMed Pelvic Pain Diary is the most comprehensive tool available for this condition today. It can help patients obtain a thorough assessment of their condition, talk more effectively with their medical providers, describe more efficiently the type and location of their pain, and give a more detailed response to questions of which pain treatments worked and which did not.

“We are excited to make this tool available to those patients who suffer from often unbearable pain as well as the doctors and other professionals who treat them. Patients and doctors both understand that managing chronic pelvic pain is difficult enough without having to describe and track the condition. The Kevmed Pelvic Pain Diary will reduce the time needed for a doctor to assess a patient’s condition, leaving more time to plan and implement treatment. The diary will empower patients to take charge of their condition, and allow them to partner more effectively with the providers who are caring for them,” says David Wiseman, PhD, Founder and CEO of KevMed.

Pain diaries and assessment tools for a number of conditions have evolved over many years with the work of the International Pelvic Pain Society and the Vulval Pain Society contributing greatly to this field. Building on this strong foundation, the KevMed Pelvic Pain Diary is the result of a collaboration with the International Adhesions Society (IAS), also founded by Dr. Wiseman, which provides information, support, and advocacy to patients and their families suffering from ARD and Complex Abdominal & Pelvic Pain Syndrome (CAPPS). Pioneering patient-centered research conducted by the International Adhesions Society (IAS) has led not only to new understandings of these conditions, but also new understandings on how to assess them and to track their progress. This knowledge was applied in developing the KevMed Pelvic Pain Diary.

The diary includes modules on bladder, bowel, abdominal, musculoskeletal and genital pain. It can be used by men and women and allows documentation of pain that is or is not related to periods (menstruation). There are also modules to document sleep, often affected adversely by pain, general daily activities and drug or other treatment.

Notes Dr. Wiseman, “Our diary is a work in progress and we invite comments and suggestions on how we can improve this for both patients and medical providers. We hope in the future to produce print versions as well as mobile and online versions that are HIPAA compliant and that can be shared with providers. We hope also to expand the diary to include more detailed sections for conditions such as fibromyalgia, temporomandibular joint (TMJ) disorders (TMD) and reflex sympathetic dystrophy (RSD) or complex regional pain syndrome (CRPS).”

The KevMed Pelvic Pain Diary can be downloaded free of charge after registration at: http://www.kevmed.com/PainDiary.html

About KevMed
Founded by David Wiseman, PhD, in 2012, KevMed LLC is a medical device company dedicated to the relief of chronic pelvic pain and related disorders. KevMed markets PainShield® MD, a wearable therapeutic ultrasound device as a non-invasive, low-risk treatment modality for chronic pelvic pain and pain associated with related conditions. KevMed, LLC was born from the work of the International Adhesions Society (IAS), which provides information, support, and advocacy to patients and their families suffering from Adhesion Related Disorder (ARD) and Complex Abdominal and Pelvic Pain Syndrome (CAPPS).

October 24 2012: New Device Dramatically Reduces Pain in Chronic Pelvic Pain and Interstitial Cystitis Patients, Finds Clinical Study Presented to the International Pelvic Pain Society

Clinical efficacy data for PainShield, a new wearable ultrasound device, showed a significant reduction in pelvic pain and related symptoms in patients with long-standing, difficult to treat chronic pelvic pain. Over 15 million patients in the U.S. suffer from chronic pelvic pain with very few effective treatment options currently available. The PainShield device promises to be a non-invasive, drug-free alternative for pain management in patients who suffer from debilitating pelvic pain.

Chicago, IL (PRWEB) October 24, 2012 (Original press release here)

In a poster presentation at the International Pelvic Pain Society Annual Meeting in Chicago (Oct. 18-21, 2012), clinical efficacy data on a new therapeutic ultrasound device, PainShield®, revealed promising result for millions of pelvic pain and interstitial cystitis sufferers in the United States.

Nineteen patients suffering from long standing and unrelieved pelvic, urological or related pain participated in the study, which found significant reductions in pelvic pain, bladder pain, pain on urination (dysuria), pain on defecation (dyschezia), abdominal bloating and muscle or joint pain related to their condition. Reductions in urinary urgency and frequency, difficulty urinating, sacro-iliac joint pain, painful intercourse (dyspareunia), rectal pain, and sitting intolerance were also noted and expected to show statistical significance in a larger study.

Over half of the trial participants rated their response to the treatment with PainShield as “good”, with only two participants rating their response as negative. Based on these positive findings, further study of PainShield as a treatment alternative to drugs and surgery is clearly warranted. Five months after starting treatment with the PainShield device, Michelle Brown, a 45-year old mother of two, who has been suffering from debilitating pelvic pain for more than a decade, reported that “I have come off all my pain medications, which used to cost me between $300 and $1000 per month.” Ms. Brown added “I feel great! I haven’t felt this good in 15 years.”

 
Click here to view video presentation.

The PainShield clinical study resulted from a grassroots effort under the leadership of a patient advocacy organization, the International Adhesions Society (IAS), which provides information, support and advocacy to patients and their families suffering from adhesion related disorder (ARD) and Complex Abdominal and Pelvic Pain Syndrome (CAPPS). The study follows other innovative research conducted by the International Adhesions Society, which has led to more patient-centered insights into this poorly understood medical condition and to the founding of the world’s first dedicated clinic for the treatment of adhesions and Complex Abdominal and Pelvic Pain Syndrome (CAPPS). The PainShield study is an example of what a patient advocacy group can accomplish with few resources other than patients seeking answers working closely with a leader in the field, in this case David Wiseman, PhD, MRPharmS, the founder of the IAS. Authoring the study together with Dr. Wiseman was Ms. Teena Petree, PT of Summit Physical Therapy, Dallas, TX, whose specialties include pelvic floor dysfunction and pelvic pain relief.

The International Adhesions Society was founded and funded by Synechion, Inc., a research and consulting company specializing in the field of surgical adhesions and pelvic pain and based on the internationally recognized expertise of its founder, Dr. David Wiseman who remarked, “after conducting research on adhesions and pelvic pain and working with patients suffering from these conditions for over 25 years, I feel that for the first time we have a real chance to revolutionize the management of pain in these patients without the risks of surgery or drugs." Added Wiseman, “the results in the PainShield study were so compelling and the clinical need so urgent, that forming a company, KevMed, to fill the needs of this underserved patient population was the logical next step. We therefore secured the US distribution and marketing rights to PainShield for patients with pelvic pain, interstitial cystitis and related conditions.”

PainShield is a wearable therapeutic ultrasound device, available by prescription to patients in the United States and was developed by NanoVibronix of Farmingdale, New York, based on its proprietary technology which miniaturizes the ultrasound delivery system to a small disc mounted within an adhesive patch applied to the skin. NanoVibronix provided the PainShield units for the study free of charge.

For more information contact:
Dr. David Wiseman
International Adhesions Society
6757 Arapaho Road, Suite 711-238
Dallas, TX 75248
http://www.adhesions.org

KevMed, LLC.
15305 Dallas Parkway, Suite 300
Addison, TX 75001
http://www.kevmed.com

October 16 2012: KevMed Prepares to Introduce Novel Device for Pelvic Pain and Interstitial Cystitis as US Distributor of PainShield

KevMed announces that it has been appointed as the US distributor of the PainShield device for treatment of pelvic pain and related conditions by NanoVibronix, a company that develops innovative medical products based on its proprietary miniaturised ultrasound technology. PainShield is a wearable device that delivers low frequency, therapeutic ultrasound for the treatment of pain associated with a number of pelvic and abdominal conditions including interstitial cystitis, irritable bowel syndrome and chronic pelvic pain. 

Dallas, TX (PRWEB) October 16, 2012

NanoVibronix®, Inc., a medical device company, which develops innovative therapeutic ultrasound products, has named KevMed™, LLC as its US distributor for PainShield®, the first hands-free, wearable therapeutic ultrasound device to treat the over 15 million patients in the USA with pelvic pain, interstitial cystitis and related conditions.

With over 25 years of experience in the area of abdominal adhesions and pelvic pain syndromes, David Wiseman, PhD, President of KevMed is excited to introduce the PainShield device to help alleviate pelvic pain in patients with chronic and difficult to treat symptoms. "In a clinical study, we found the PainShield ultrasound therapy to dramatically reduce pain in CAPPS (Complex Abdominal and Pelvic Pain Syndrome) patients. An abstract with clinical data reflecting this positive finding was accepted for presentation at the upcoming meeting of the International Pelvic Pain Society (IPPS) 2012 in Chicago," says Wiseman. "I feel that for the first time, we have a real chance to revolutionize the management of pain in these patients without the risks of surgery or drugs."

According to Amir Rippel, VP Marketing at NanoVibronix, "our relationship with KevMed will allow us to reach many patients suffering from pain due to various pelvic pain syndromes. PainShield can help pelvic pain patients overcome their daily suffering and return to a more normal life." Rippel adds, "following our ongoing success in relieving pain for patients with trigeminal neuralgia, an extremely painful neurological facial syndrome, we believe we can reduce the suffering and improve quality of life for many other patients with specific, but difficult to treat pain."

PainShield is the first hands-free, low-frequency therapeutic ultrasound device that delivers therapy via a self-adhering patch. The portable design allows for an entirely new dimension in ultrasound treatment of pain and soft tissue healing. PainShield consists of a disposable patch connected to a portable reusable driver and transmits ultrasound waves to the desired area of the body. Patients can use PainShield in the clinical setting, at home, at work, and even while they sleep. The hassle-free, user-friendly application of the device dramatically improves patient compliance and access to treatment. PainShield is cleared by the FDA for treatment of pain and carries the CE Mark.

Over 15 million patients in the US suffer from a number of overlapping disorders that include pelvic pain, abdominal pain, Adhesion Related Disorder (ARD), bowel obstruction, endometriosis, interstitial cystitis (IC), painful bladder syndrome, irritable bowel syndrome (IBS), vulvodynia, dyspareunia (painful intercourse), dyschezia (painful defecation), adhesions, sacroiliac joint pain, pudendal neuralgia and pelvic floor dysfunction. Numerous patients undergo hysterectomy in an effort to alleviate their pain, only to discover that the procedure worsens their condition. In extreme cases, patients will also report fibromyalgia, temporomandibular joint (TMJ) disorders (TMD) and reflex sympathetic dystrophy (RSD) or complex regional pain syndrome (CRPS). Collectively, these conditions have been termed CAPPS (Complex Abdominal and Pelvic Pain Syndrome). PainShield is designed to help relieve the pain associated with these conditions.

About KevMed
KevMed, LLC was born from the work of the International Adhesions Society (IAS), which provides information, support, and advocacy to patients and their families suffering from Adhesion Related Disorder (ARD) and Complex Abdominal and Pelvic Pain Syndrome (CAPPS). The International Adhesions Society (IAS) was founded by Synechion, Inc. in 1996 in response to demand by pelvic pain patients seeking answers in a field that remains poorly understood by many patients and clinicians. Synechion, Inc. is a consulting company specializing in the science and business of adhesions, founded by David Wiseman, PhD, MRPharmS, internationally recognized expert who has been making important product and scientific contributions to the field since 1987. Research by the International Adhesions Society (IAS) has revealed new understandings of Adhesion Related Disorder (ARD) and related conditions from the perspective of the patient, resulting in the identification of PainShield® as an effective treatment for pelvic pain.

Contact:
Dr. David Wiseman, President
KevMed™, LLC
15305 Dallas Parkway, Suite 300, Addison, TX 75001
972 931 5596
david.wiseman(at)kevmed(dot)com
http://www.kevmed.com
About NanoVibronix®
Located in Farmingdale, New York, with a subsidiary in Nesher, Israel, NanoVibronix® develops medical devices that utilize its proprietary therapeutic ultrasound technology. In addition to the PainShield® product for pain, the company is expanding its portable, therapeutic platform to the WoundShield® device - targeting expedited healing of chronic and acute wounds. NanoVibronix has also developed and markets the UroShield® catheter-based, disposable ultrasound, intended to reduce pain and discomfort and help prevent UTI in indwelling urinary catheters.

Contact:
Amir Rippel
NanoVibronix Ltd.
Tel: +972 4 820 0581
info@nanovibronix.com
http://www.nanovibronix.com

Original Page on PRWeb here.

_______________________________________________

_______________________________________________

October 10 2012: Chronic Pelvic Pain and Interstitial Cystitis Patients Soon to Have New Treatment Options with Formation of KevMed, LLC

Synechion, Inc., a research and consulting company specializing in the prevention of adhesions - internal scars causing pain and other complications - has announced the formation of a new company, KevMed, LLC to commercialize break-through innovations for the treatment of chronic pelvic pain and related disorders. Over 15 million patients in the U.S. suffer from chronic pelvic pain with very few effective treatment options currently available.

Dallas, TX, (PRWEB) October 10, 2012

Synechion Inc., a research and consulting company specializing in the field of surgical adhesion (internal scar tissue) prevention, has announced the formation of KevMed, LLC. KevMed will commercialize new technologies for the treatment of chronic pelvic pain and related disorders. Over 15 million patients in the U.S. suffer from chronic pelvic pain for which very few effective treatment options are available. KevMed’s technology will provide safe and non-invasive pain therapy for these patients.

Research conducted by Synechion through its patient support and advocacy organization, the International Adhesions Society (IAS), has revealed that vast numbers of primarily female patients, debilitated by chronic pelvic and abdominal pain, are poorly served by current medical approaches.

According to David Wiseman, PhD, Founder and President of KevMed, “The founding of KevMed is a natural extension of our work spanning more than two decades, which has helped to make valuable contributions to the field of surgical adhesions. Not only have we played a pivotal role in the development of a number of anti-adhesions products, but our work with the International Adhesions Society (IAS) led to the founding of the world’s first dedicated clinic for the treatment of adhesions and Complex Abdominal and Pelvic Pain Syndrome (CAPPS). Our ground-breaking research has allowed us to better understand the needs of the adhesions and chronic pelvic pain patient. To serve these unmet needs, we have established KevMed.”

Adds Wiseman, “Patients suffering from chronic pelvic pain require an integrated treatment approach from a multi-disciplinary clinical team. Companies like KevMed, with a strong understanding of these patients’ needs, can support the multi-disciplinary approach with innovative, patient-centric technology. Our track record in research and patient service places KevMed in a unique position to serve patients with chronic pelvic pain.”

Over 15 million patients in the USA suffer from a number of overlapping disorders that include pelvic pain, abdominal pain, Adhesion Related Disorder (ARD), bowel obstruction, endometriosis, interstitial cystitis (IC), painful bladder syndrome, irritable bowel syndrome (IBS), vulvodynia, dyspareunia (painful intercourse), dyschezia (painful defecation), adhesions, sacroiliac joint pain, pudendal neuralgia and pelvic floor dysfunction. Numerous patients undergo hysterectomy in an effort to alleviate their pain, only to discover that the procedure worsens their condition. In extreme cases, patients will also report fibromyalgia, temporomandibular joint (TMJ) disorders (TMD) and reflex sympathetic dystrophy (RSD) or complex regional pain syndrome (CRPS). KevMed’s mission is to provide safe and non-invasive pain therapy to these patients.

About Synechion, Inc. and the International Adhesions Society (IAS)
Synechion, Inc. is a consulting company specializing in the science and business of post-operative adhesions, founded by David Wiseman, PhD, MRPharmS, internationally recognized expert who has been making important product and scientific contributions to the field since 1987. The International Adhesions Society (IAS) was founded by Synechion, Inc. in 1996 in response to demand by pelvic pain patients seeking answers in a field that remains poorly understood by many patients and clinicians.

Original page on PRWeb here